Sufentanil/Triazolam

舒芬太尼/三唑仑

Report date: 2025/02/21 20:00:37

Base Information

Drug NameSufentanil/Triazolam
Drug Alias NameSufentanil-Triazolam mixt舒芬太尼+三唑仑舒芬太尼-三唑仑复方Sufentanil●Triazolam舒芬太尼和三唑仑 +[16] 
ClassificationSmall molecules
Mechanisms of ActionOpioid receptors agonistsGamma-aminobutyric acid A receptor agonists
TargetsOpioid receptorsGamma-aminobutyric acid A receptor
Therapy Area/IndicationsSedationAnxietyCancer Pain +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsYes Sufentanil CitrateTriazolam
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTalphera Inc
China Registration ClassN/A

Develop Information

Active CompaniesYichang Humanwell Pharmaceutical Co Ltd
Inactive CompaniesTalphera Inc
Active IndicationsCancer Pain
Inactive IndicationsSedationAnxietyPain

Other Information

ATC CodeN/A
Related LinksN/A